Carlsmed, Inc

Carlsmed’s commercial focus is currently the United States, where it markets and sells through a direct sales team and independent sales agents. The company’s headquarters and primary operating base are in Carlsbad, California, which also anchors its corporate and administrative functions. Management has stated that it plans to evaluate strategic international regions in the future, but international sales are not yet a meaningful part of the business. Geography matters because the company’s current revenue base is concentrated in one market, while future expansion will require regulatory, reimbursement, and distribution capabilities outside the U.S. The business also relies on U.S.-based clinical adoption and hospital approval processes, which shape the pace of commercialization.

Carlsmed depends entirely on sales of aprevo interbody implants, so adoption risk is central: if surgeons and hospitals do not embrace the platform, revenue growth can stall quickly. The company also relies on a limited number of contract manufacturing organizations for manufacturing, sterilization, packaging, and distribution, which creates supply continuity and quality-control risk. Because the business is still scaling, it faces execution risk in building a larger sales force, managing independent sales agents, and converting clinical interest into recurring procedure volume. The company operates in a highly competitive spine device market against much larger incumbents, and pricing, reimbursement, and product innovation by competitors could pressure growth. As a medical device company, it also faces regulatory, cybersecurity, reimbursement, and clinical evidence risks that can affect commercialization and margins.